rhIL-11联合MEA方案治疗急性髓细胞白血病  

Clinical Effect of rhIL-11 Associated with Chemotherapy of MEA on Acute Myelogenous Leukemia

作　　者：陈玉清[1] 李琳[2] 张茵[1] 臧玉柱[1] 郭建民[1] 

机构地区：[1]河南省人民医院血液科,郑州市450003 [2]第一军医大学附属南方医院血液科,广州市510515

出　　处：《医药论坛杂志》2005年第15期29-30,共2页Journal of Medical Forum

摘　　要：目的探讨重组人白介素-11(rhIL-11)联合MEA方案治疗急性髓细胞白血病的疗效。方法48例急性髓细胞白血病分为2组:治疗组26例,给予rhIL-11和MEA方案化疗;对照组22例,给予MEA方案化疗而不用rhIL-11。动态观察化疗后血小板数值变化及rhIL-11的不良反应。结果rhIL-11能显著增加治疗组患者血小板数量(P<0.01),缩短血小板数值恢复正常所需时间(P<0.01),不良反应以乏力、水肿和注射部位疼痛为主。结论rhIL-11有明显的促血小板生成作用,不良反应轻微,与化疗联用可减少出血并发症,使化疗顺利进行。Objective To study the effect of rhIL-11 associate with chemotherapy of MEA on acute myelogenous leukemia. Methods 48 cases of acute myelogenous leukemia were divided into 2 groups： treatment group and control group. The treatment group （26 cases） used both rhIL-11 and MEA project, the control group （22 cases） used MEA project only. We observed the developing change of platelet and side effects of rhIL-11. Results rhIL-11 could significantly increase platelet number （P〈0.01） and shorten recovery time of platelet （P〈0.01）. The main side effects included fatigue, edema and injection pain. Conclusion rhIL-11 could elevate nadirs of thrombocytopenia with acceptable mild side effects, decrease complication of bleeding and facilitate chemotherapy.

关 键 词：RHIL-11 MEA方案 急性髓细胞白血病 

分 类 号：R733.71[医药卫生—肿瘤]